| Description: | CuraGen Corporation (NASDAQ: CRGN) is a genomics-based pharmaceutical company dedicated to improving the lives of patients by developing novel pharmaceutical products that address unmet medical needs. CuraGen's deep understanding of the human genome has enabled us to gain greater insight into the molecular basis of disease. Our therapeutics are based on novel targets from the human genome that play a role in proven mechanisms underlying disease. We have translated this understanding into a broad pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, obesity and diabetes. The Company's strategy continues to be focused on delivering on the promise of genomics by turning the genome into drugs. |
|---|
